GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Interest Received

Oncopeptides AB (OSTO:ONCO) Interest Received


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.


Oncopeptides AB Business Description

Traded in Other Exchanges
Address
Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and, in particular, multiple myeloma.